Anti-proliferation and apoptosis induced by a novel intestinal metabolite of ginseng saponin in human hepatocellular carcinoma cells

Cell Biology International

Volumn 31, Issue 10, 2007, Pages 1265-1273

  Ming, Yan lin ^a,b   Song, Gang ^a   Chen, Liang hua ^b   Zheng, Zhi zhong ^b   Chen, Zhong yan ^b   Ouyang, Gao liang ^a   Tong, Qing xuan ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Xiamen Overseas Chinese Subtropical Plant Introduction Garden   (China)

Author keywords

Anti proliferation; Apoptosis; Human hepatocellular carcinoma cells; IH 901; SMMC7721

Indexed keywords

20 O (BETA DEXTRO GLUCOPYRANOSYL)PROTOPANAXADIOL; GINSENG SAPONIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; METABOLITE; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CASPASES; CELL PROLIFERATION; CYTOCHROMES C; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SAPOGENINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

BACTERIA (MICROORGANISMS); PANAX GINSENG;

EID: 34447288092     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.05.005     Document Type: Article

References (41)

1. Adams J.M., and Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281 (1998) 1322-1326
2. Akao T., Kanaoka M., and Kobashi K. Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay. Biol Pharm Bull 21 (1998) 245-249
3. Akao T., Kida H., Kanaoka M., Hattori M., and Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 50 (1998) 1155-1160
4. Attele S.A., Wu J.A., and Yuan C.S. Ginseng pharmacology, multiple constitutes and multiple actions. Biochem Pharmacol 58 (1999) 1685-1693
5. Bae E.A., Choo M.K., Park E.K., Park S.Y., Shin H.Y., and Kim D.H. Metabolism of ginsenoside Rc by human intestinal bacteria and its related antiallergic activity. Biol Pharm Bull 25 (2002) 743-747
6. Bae E.A., Park S.Y., and Kim D.H. Constitutive beta-glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull 23 (2000) 1481-1485
7. Choi H.H., Jong H.S., Park J.H., Choi S., Lee J.W., Kim Y.Y., et al. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells. Int J Oncol 23 (2003) 1087-1093
8. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 340 (1999) 745-750
9. Gross A., McDonnell J.M., and Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13 (1999) 1899-1911
10. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside: deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 95 (2004) 153-157
11. Hasegawa H., Matsumiya S., Uchiyama M., Kurokawa T., Inouye Y., Kasai R., et al. Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities. Planta Med 60 (1994) 240-243
12. Hasegawa H., Sung J.H., and Huh J.D. Ginseng intestinal bacteria metabolite IH-901 as a new antimetastatic agent. Arch Pharm Res 20 (1997) 539-544
13. Hasegawa H., Sung J.H., Matsumiya S., and Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 62 (1996) 453-457
14. Hasegawa H., Sung J.H., Matsumiya S., Uchiyama M., Inouye Y., Kasai R., et al. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med 61 (1995) 409-413
15. Hasegawa H., Suzuki R., Nagaoka T., Tezuka Y., Kadota S., and Saiki I. Prevention of growth and metastasis of murine melanoma through enhanced natural-killer cytotoxicity by fatty acid-conjugate of protopanaxatriol. Biol Pharm Bull 25 (2002) 861-866
16. Herr I., and Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 98 (2001) 2603-2614
17. Howe H.L., Wingo P.A., Thun M.J., Ries L.A., Rosenberg H.M., Feigal E.G., et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93 (2001) 824-842
18. Kobashi K., Akao T., Hattori M., and Namba T. Metabolism of drugs by intestinal bacteria. Bifidobact Microflora 11 (1992) 9-23
19. Kobashi K., and Akao T. Relation of intestinal bacteria to pharmacological effects of glycosides. Biosci Microflora 16 (1997) 1-7
20. Korsmeyer S.J., Wei M.C., Saito M., Weiler S., Oh K.J., and Schlesinger P.H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 7 (2000) 1166-1173
21. Kim Y.S., Jin S.H., Lee Y.H., Kim S.I., and Park J.D. Ginsenoside Rh2 induces apoptosis independently of Bcl-2, Bcl-xL, or Bax in C6Bu-1 cells. Arch Pharm Res 22 (1999) 448-453
22. Lee B.H., Lee S.J., Hur J.H., Lee S., Sung J.H., Huh J.D., et al. In vitro antigenotoxic activity of novel ginseng saponin metabolites formed by intestinal bacteria. Planta Med 64 (1998) 500-503
23. Lee J.Y., Shin J.W., Chun K.S., Park K.K., Chung W.Y., Bang Y.J., et al. Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin. Carcinogenesis 26 (2005) 359-367
24. Lee S.J., Ko W.G., Kim J.H., Sung J.H., Moon C.K., and Lee B.H. Induction of apoptosis by a novel intestinal metabolite of ginseng saponin via cytochrome c-mediated activation of caspase-3 protease. Biochem Pharmacol 60 (2000) 677-685
25. Lee S.J., Sung J.H., Lee S.J., Moon C.K., and Lee B.H. Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin. Cancer Lett 144 (1999) 39-43
26. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
27. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
28. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
29. Ogunbiyi J.O. Hepatocellular carcinoma in the developing world. Semin Oncol 28 (2001) 179-187
30. Oh S.H., and Lee B.H. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase-8 activation and Bid cleavage. Toxicol Appl Pharmacol 194 (2004) 221-229
31. Oh S.H., Yin H.Q., and Lee B.H. Role of the Fas/Fas ligand death receptor pathway in ginseng saponin metabolite-induced apoptosis in HepG2 cells. Arch Pharm Res 27 (2004) 402-406
32. Park E.K., Choo M.K., Han M.J., and Kim D.H. Antiallergic and antiinflammatory activities of ginsenoside Rh1. Int Arch Allergy Immunol 133 (2004) 113-120
33. Shin H.R., Kim J.Y., Yun T.K., Morgan G., and Vainio H. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Cause Control 11 (2000) 565-576
34. Srinivasula S.M., Ahmad M., Fernandes-Alnemri T., and Alnemri E.S. Autoactivation of procaspase 9 by Apaf-1-mediated oligomerization. Mol Cell 1 (1998) 949-957
35. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144 (1999) 281-292
36. Tanaka N., Tanaka O., and Shibata S. Chemical studies on the Oriental plant drugs. XXVIII. Saponins and sapogenins of ginseng: stereochemistry of sapogenin of ginsenoside Rb1, Rb2 and Rc. Chem Pharm Bull 20 (1972) 1212-1216
37. Taylor-Robinson S.D., Foster G.R., Arora S., Hargreaves S., and Thomas H.C. Increase in primary liver cancer in the UK 1979-94. Lancet 350 (1997) 1142-1143
38. Wakabayashi C., Hasegawa H., Murata J., and Saiki I. In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration. Oncol Res 9 (1997) 411-417
39. Wakabayashi C., Hasegawa H., Murata J., and Saiki I. The expression of in vivo anti-metastatic effect of ginseng protopanaxatriol saponins is mediated by their intestinal bacterial metabolites after oral administration. J Trad Med 14 (1997) 180-185
40. Wakabayashi C., Murakami K., Hasegawa H., Murata J., and Saiki I. An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells. Biochem Biophys Res Commun 246 (1998) 725-730
41. Yim H.W., Jong H.S., Kim T.Y., Choi H.H., Kim S.G., Song S.H., et al. Cyclooxygenase-2 inhibits novel ginseng metabolite-mediated apoptosis. Cancer Res 65 (2005) 1952-1960